Jike Hu

Jan 14, 2025 | bmccancer.biomedcentral.com | Lijuan He |Haiyuan Li |Ben Liu |Yunpeng Wang |Bo Xu |Jike Hu | +6 more

This study applied a prospective, observational (non-randomized) design, recruiting patients receiving anticancer agents from March 2021 to August 2021. This work didn’t interfere with clinical decision-making or risk beyond conventional treatment, enrolling and following only patients prescribed fosaprepitant. No identifiable information will be included in the recorded data to protect the privacy of the subjects.